MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 18.03.2026
Marker Therapeutics Kurzfristige Verbindlichkeiten 2011-2026 | MRKR
Kurzfristige Verbindlichkeiten Jährlich Marker Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.27 M | 3.46 M | 3.07 M | 7.78 M | 12.9 M | 6.4 M | 1.99 M | 2.8 M | 1.52 M | 1.74 M | 28 M | 1.25 M | 8.85 M | 5.77 M | 3.8 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 28 M | 1.25 M | 6.11 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M |  USA |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
12.4 M | $ 5.46 | 6.64 % | $ 368 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
21.2 M | $ 6.61 | -13.71 % | $ 65.3 M | USA |
 |
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.47 B | $ 310.78 | -2.92 % | $ 40.7 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 22.7 | 4.08 % | $ 1.06 B | USA |
 |
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.04 | -1.3 % | $ 5 M |  Israel |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioXcel Therapeutics
BTAI
|
53.9 M | $ 1.18 | 9.81 % | $ 14.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
163 M | $ 1.44 | 6.67 % | $ 370 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.36 | 2.35 % | $ 466 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
130 M | $ 24.65 | 1.9 % | $ 3.14 B | USA |
 |
Celldex Therapeutics
CLDX
|
51 M | $ 34.97 | 3.28 % | $ 2.32 B | USA |
 |
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | USA |
 |
Cabaletta Bio
CABA
|
50.2 M | $ 3.37 | -4.4 % | $ 339 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.65 | 2.48 % | $ 439 M | Britain |
 |
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | USA |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Cidara Therapeutics
CDTX
|
49.6 M | - | - | $ 1.41 B | USA |
 |
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | USA |